Next Article in Journal
Leveraging Dissolution by Autoinjector Designs
Next Article in Special Issue
Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level
Previous Article in Journal
Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response
Previous Article in Special Issue
Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics

1
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India
2
Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia
3
Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia
4
School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jaipur 302017, India
5
Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, India
6
Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun 248007, India
7
School of Health Sciences, The University of Tasmania, Launceston, TAS 7248, Australia
8
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2022, 14(11), 2543; https://doi.org/10.3390/pharmaceutics14112543
Submission received: 30 September 2022 / Revised: 7 November 2022 / Accepted: 19 November 2022 / Published: 21 November 2022
(This article belongs to the Special Issue Targeted Therapies in Diabetes and Its Complications)

Abstract

Diabetic foot ulcer (DFU) is a multifactorial disease and one of the complications of diabetes. The global burden of DFU in the health sector is increasing at a tremendous rate due to its cost management related to hospitalization, medical costs and foot amputation. Hence, to manage DFU/DWs, various attempts have been made, including treating wounds systematically/topically using synthetic drugs, herbal drugs, or tissue engineering based surgical dressings. However, less attention has been paid to the intrinsic factors that are also the leading cause of diabetes mellitus (DM) and its complications. One such factor is gut dysbiosis, which is one of the major causes of enhancing the counts of Gram-negative bacteria. These bacteria produce lipopolysaccharides, which are a major contributing factor toward insulin resistance and inflammation due to the generation of oxidative stress and immunopathy. These all lead to DM and DFU. Probiotics are the commercial form of beneficial gut microbes that are taken as nutraceuticals by people of all ages to improve gut immunity and prevent gut dysbiosis. However, the role of probiotics has been less explored in the management of DFU. Hence, the therapeutic potential of probiotics in managing DFU is fully described in the current review. This report covers the linkage between gut dysbiosis and DFU, sources of probiotics, the mechanisms of probiotics in DW healing, and the impact of probiotic supplementation in treating DFU. In addition, techniques for the stabilization of probiotics, market status, and patents related to probiotics have been also covered. The relevant data were gathered from PubMed, Scopus, Taylor and Francis, Science Direct, and Google Scholar. Our systematic review discusses the utilization of probiotic supplementation as a nutraceutical for the management of DFU.
Keywords: diabetic foot ulcer; pathogenesis; sources of probiotics; therapeutic potential of probiotics on DFU; market status of probiotics; patents on probiotics diabetic foot ulcer; pathogenesis; sources of probiotics; therapeutic potential of probiotics on DFU; market status of probiotics; patents on probiotics

Share and Cite

MDPI and ACS Style

Awasthi, A.; Corrie, L.; Vishwas, S.; Gulati, M.; Kumar, B.; Chellappan, D.K.; Gupta, G.; Eri, R.D.; Dua, K.; Singh, S.K. Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics. Pharmaceutics 2022, 14, 2543. https://doi.org/10.3390/pharmaceutics14112543

AMA Style

Awasthi A, Corrie L, Vishwas S, Gulati M, Kumar B, Chellappan DK, Gupta G, Eri RD, Dua K, Singh SK. Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics. Pharmaceutics. 2022; 14(11):2543. https://doi.org/10.3390/pharmaceutics14112543

Chicago/Turabian Style

Awasthi, Ankit, Leander Corrie, Sukriti Vishwas, Monica Gulati, Bimlesh Kumar, Dinesh Kumar Chellappan, Gaurav Gupta, Rajaraman D. Eri, Kamal Dua, and Sachin Kumar Singh. 2022. "Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics" Pharmaceutics 14, no. 11: 2543. https://doi.org/10.3390/pharmaceutics14112543

APA Style

Awasthi, A., Corrie, L., Vishwas, S., Gulati, M., Kumar, B., Chellappan, D. K., Gupta, G., Eri, R. D., Dua, K., & Singh, S. K. (2022). Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics. Pharmaceutics, 14(11), 2543. https://doi.org/10.3390/pharmaceutics14112543

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop